Topical Corticosteroid Rx-To-OTC Switch Safety To Be Considered By NDAC
This article was originally published in The Tan Sheet
Executive Summary
The Nonprescription Drugs and Dermatologic & Ophthalmic Drugs (DODAC) advisory committees will discuss guidelines on adequate safety information when considering Rx-to-OTC switches of topical corticosteroids during a March 24 meeting